160 related articles for article (PubMed ID: 30463432)
1. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Streitová H; Bareš M
Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
4. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
6. THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.
Gaćina K; Lešin M; Sarajčev D; Rotim N
Acta Clin Croat; 2022 Nov; 61(3):379-385. PubMed ID: 37492354
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
9. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
Lee S; Park S; Lew H
Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with blepharospasm.
Biuk D; Karin AA; Matić S; Barać J; Benasić T; Stiglmayer N
Coll Antropol; 2013 Mar; 37(1):29-33. PubMed ID: 23697247
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
12. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
13. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
14. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
MacAndie K; Kemp E
Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
16. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
[TBL] [Abstract][Full Text] [Related]
17. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm.
Johnstone SJ; Adler CH
Headache; 1998 May; 38(5):366-8. PubMed ID: 9630789
[TBL] [Abstract][Full Text] [Related]
18. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
[TBL] [Abstract][Full Text] [Related]
19. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm.
Weiss D; Hieber L; Sturm J; Börtlein A; Buchthal J; Dippon C; Arnold G; Wächter T
Clin Neurol Neurosurg; 2018 Sep; 172():130-133. PubMed ID: 29990961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]